Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease

NCT01047579 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01047579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01047579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2010
Completion date
January 31, 2012
Enrollment
51 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease